Navigation Links
Xybion Completes Acquisition of Stelex and Vital-Path, Leaders in Business Process Software and Consulting Services for Regulated Industries, from GE Healthcare
Date:5/12/2010

Acquisition Extends Consulting and Implementation Capabilities and Software Offerings of Xybion Corporation

(PRWEB) May 12, 2010 -- Xybion Corporation announced today that it has completed the acquisition of substantially all of the operating assets of Stelex and Vital-Path from GE Healthcare. The terms of the transactions were not disclosed.

Stelex and Vital-Path, based in Bensalem, PA is a strategic addition to Xybion’s enterprise software and consulting solutions focus for the life sciences, finance, manufacturing and other regulated industries. Stelex and Vital-Path provide a range of products and services to regulated industries such as:

- Asset and Facilities Management solutions including services and support for IBM’s Maximo, a leading software solution that enables the user to develop comprehensive programs for preventive, predictive, routine and unplanned maintenance for assets and facilities

- Enterprise Content Management and Migration solutions to assist clients in taking control of their mission critical content and to seamlessly share data among disparate departmental content repositories

- Regulatory Compliance solutions and System integration and implementation services for regulated industries.

The acquisition will extend Xybion’s software, consulting and Implementation capabilities and increase the company’s enterprise client base.

“The addition of Stelex and Vital-Path will a
'/>"/>

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Xybion Unveils Pristima™ VM, an Integrated Enterprise Software Solution for Vivarium and Veterinary Care Management
2. Korea Institute of Toxicology Implementing Xybion's Pristima™
3. Nile Therapeutics Completes Dose Escalation in Ongoing Phase II Study
4. Hendrick Construction Completes Oak Ridge National Laboratory Expansion
5. Oncolytics Biotech(R) Inc. Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial
6. Therapeutic Proteins Inc. Completes First Independent, Dedicated Biosimilars Manufacturing Facility in U.S.
7. NOVAVAX Completes Enrollment of Pivotal H1N1 Influenza Vaccine Clinical Trial in Mexico
8. EUSA Pharma Completes Establishment of Commercial Infrastructure With Appointment of President for Europe and International Region
9. APT Pharmaceuticals Completes Enrollment in Phase III for Inhaled Cyclosporine
10. Ocera Therapeutics Completes Phase 2B Enrollment in the ASTUTE Trial
11. Neuralstem Completes $5.25 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 2013 Northwest Biotherapeutics (NASDAQ: NWBO ... personalized immune therapies for solid tumor cancers, announced ... year,s American Society Of Clinical Oncology (ASCO) meeting in ... role in immune therapy.  (Logo: http://photos.prnewswire.com/prnh/20110329/SF73084LOGO ... the pre-eminent conference focused on clinical treatment of cancer, ...
(Date:5/23/2013)... May 23, 2013  Verenium Corporation (Nasdaq: ... the development and commercialization of high-performance enzymes, today announced ... Officer, will present at two upcoming conferences. ... present at the Second Annual Marcum LLP Microcap Conference ... Hotel in New York City.  The presentation is scheduled ...
(Date:5/23/2013)... 2013 SynCardia Systems, Inc. ( http://www.syncardia.com ... Health Canada and CE (Europe) approved Total Artificial Heart, ... which boasts more than 380,000 visitors annually, is featuring ... by the Freedom® portable driver as part of its ... exhibitions of its kind. , “BodyWorks combines the ...
(Date:5/23/2013)... Bed bugs compromised Penn State. ... confirmed it. Meanwhile, My Cleaning Products offered complimentary samples of ... the pests without using harmful chemical elements. , Based ... the affected building was actually a dormitory , My ... made on May 13 and bed bug presence was confirmed ...
Breaking Biology Technology:NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 2NW Bio Exhibit at the Upcoming ASCO Meeting to Highlight its Leadership Role in Immune Therapy for Cancer 3Verenium To Present At Two Upcoming Conferences 2Verenium To Present At Two Upcoming Conferences 3SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 2SynCardia Total Artificial Heart Featured in $3 Million Exhibition at Glasgow Science Centre 3Penn State Dorm Infested with Bed Bugs, My Cleaning Products Offers Complimentary Sample of Bed Bug Spray to Help Bed Bug Victims 2
... REDWOOD CITY, Calif., Feb. 1, 2012 Codexis, Inc. ... enzymes to enable affordable and abundant sugar for the ... company will be participating in the following upcoming investor ... 2012Time: , 10:00 a.m. PT (Panel: The Rise of ...
... 2012 Alchem International Ltd. opens its ... marketing office will be spearheaded by Laurent Leduc, former ... cater to the rapidly growing demand in North America ... for the supplement, pharmaceutical and cosmetic industries. ...
... BOSTON and SEOUL, Korea, Feb. 1, 2012   PAREXEL ... leading global biopharmaceutical services provider, announced today that it ... Center (AMC), based in Seoul, Korea. The alliance ... access to high quality clinical trial services throughout ...
Cached Biology Technology:Alchem International Opens Sales and Marketing Office in the U.S. 2PAREXEL and ASAN Medical Center Establish Alliance to Accelerate Korea-based Drug Development and Commercialization Programs 2PAREXEL and ASAN Medical Center Establish Alliance to Accelerate Korea-based Drug Development and Commercialization Programs 3PAREXEL and ASAN Medical Center Establish Alliance to Accelerate Korea-based Drug Development and Commercialization Programs 4PAREXEL and ASAN Medical Center Establish Alliance to Accelerate Korea-based Drug Development and Commercialization Programs 5
(Date:5/23/2013)... new mechanism by which estrogen suppresses lipid synthesis in ... new approach toward treating certain liver diseases. , ... they are changing long-held views in the field. Study ... journal Science Signaling . , "The dogma in ... that only receptors located in the nucleus respond to ...
(Date:5/23/2013)... WASHINGTON Given the implications for the overall ... should play a primary role in ensuring that ... least 60 minutes per day of vigorous or ... the Institute of Medicine. Recent estimates suggest ... this evidence-based guideline for promoting better health and ...
(Date:5/23/2013)... 2013) A new report from the Institute of ... engage in at least 60 minutes of vigorous or ... more than half of American youth meet current evidence-based ... moderate intensity physical activity daily, according to the report, ... in school for nearly half of their waking hours, ...
Breaking Biology News(10 mins):UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 3Schools should provide students with daily physical activity, IOM recommends 2
... have appeared as being in perpetual conflict, but a new ... scientists at major research universities see religion and science as ... the meaning of life, ways of understanding reality, origins of ... religion and science as being at odds and even in ...
... is the body,s armor, protecting us from disease agents, injury, ... a single gene, the gene for the protein p63, cause ... the epidermis and other tissues. In the epidermis, ... bleeding, infection, and discoloration. A research team from ...
... University of Massachusetts Amherst environmental toxicologist Edward Calabrese, ... chemicals and radiation are benign or even helpful, says ... of radiation genetics, Nobel Prize winner Hermann Muller, knowingly ... no safe level of radiation exposure. Calabrese,s ...
Cached Biology News:Science and religion do mix 2Science and religion do mix 3How key genes cooperate to make healthy skin 2How key genes cooperate to make healthy skin 3How key genes cooperate to make healthy skin 4UMass researcher points to suppression of evidence on radiation effects by 1946 Nobel Laureate 2UMass researcher points to suppression of evidence on radiation effects by 1946 Nobel Laureate 3
Human Cystatin F MAb (Clone 292103)...
... is an inhibitor of ... concentration of inhibitor required ... must be determined empirically ... micromolar inhibitor is sufficient ...
Human RELT/TNFRSF19L Affinity Purified Polyclonal Ab...
Mouse NOV/CCN3 Affinity Purified Polyclonal Ab...
Biology Products: